

## PHARMACY POLICY STATEMENT

### Indiana Medicaid

<b>DRUG NAME</b>	<b>Jascayd (nerandomilast)</b>
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Jascayd, approved by the FDA in 2025, is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients.

IPF, the most common of the interstitial lung diseases, is characterized by chronic, progressive scarring of the lungs and the pathological hallmark of usual interstitial pneumonia (UIP).

Jascayd (nerandomilast) will be considered for coverage when the following criteria are met:

#### Idiopathic Pulmonary Fibrosis (IPF)

For **initial** authorization:

1. Member is at least 18 years of age; AND
2. Medication must be prescribed by or in consultation with a pulmonologist; AND
3. Member has a diagnosis of IPF confirmed by a UIP pattern on high resolution computed tomography (HRCT) or by a lung biopsy (results must be submitted for review); AND
4. Documentation of member's baseline forced vital capacity (FVC); AND
5. Member has tried and failed Esbriet or Ofev.
6. **Dosage allowed/Quantity limit:** 18 mg orally twice daily. May reduce to 9 mg twice daily if unable to tolerate, unless concurrently taking pirfenidone. QL: 60 tablets per 30 days

***If all the above requirements are met, the medication will be approved for 6 months.***

For **reauthorization**:

1. Chart notes must show improvement or stabilized signs and symptoms of disease demonstrated by reduced rate of FVC decline.

***If all the above requirements are met, the medication will be approved for an additional 12 months.***

**CareSource considers Jascayd (nerandomilast) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.**

DATE	ACTION/DESCRIPTION
11/04/2025	New policy for created for Jascayd.

References:

IN-MED-P-366647a; Issued Date: 6/1/2023

OMPP Approved: 5/16/2023

1. Jascayd [prescribing information]. Boehringer Ingelheim Pharmaceuticals, Inc.; 2025.
2. Richeldi L, Azuma A, Cottin V, et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. *N Engl J Med*. 2025;392(22):2193-2202. doi:10.1056/NEJMoa2414108
3. Raghu G, Rochweg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2015;192(2):e3-e19. doi:10.1164/rccm.201506-1063ST
4. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2022;205(9):e18-e47. doi:10.1164/rccm.202202-0399ST

Effective date: 05/01/2026

Revised date: 11/04/2025